bioAffinity Technologies Expands Access to Lung Cancer Test
Company Announcements

bioAffinity Technologies Expands Access to Lung Cancer Test

bioAffinity Technologies, Inc. ( (BIAF) ) has provided an announcement.

bioAffinity Technologies, Inc. has announced the inclusion of its noninvasive lung cancer detection test, CyPath® Lung, on the U.S. Federal Supply Schedule, granting easy access to VHA and Military Health System facilities. This significant move will cater to the high demand for early cancer detection among veterans, who are at an increased risk of lung cancer due to various factors such as age and environmental exposures. The test, which boasts high accuracy and has the potential to save millions in healthcare costs, represents a major advancement in the quest for better cancer treatment and patient survival outcomes.

See more insights into BIAF stock on TipRanks’ Stock Analysis page.

Related Articles
Ryan AdistIs BIAF a Buy, Before Earnings?
TheFlyBioAffinity Technologies appoints William Bauta, Ph.D. Chief Science Officer
TheFlyBioAffinity Technologies issued patent by Japan Patent Office
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App